CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
50 hedge funds and large institutions have $133M invested in CTI BioPharma Corp. (DE) Common Stock in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 10 closing their positions.
84% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $600K
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
6% more capital invested
Capital invested by funds: $126M → $133M (+$7.08M)
9% less funds holding
Funds holding: 55 → 50 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$10.4M |
| 2 |
ACM
Altium Capital Management
New York
|
+$7.41M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$4.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.33M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$7.31M |
| 2 |
Morgan Stanley
New York
|
-$964K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$631K |
| 4 |
HF
HRT Financial
New York
|
-$565K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$551K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
51
Credit Suisse
Zurich,
Switzerland
| – | -$41K | -14,117 | Closed |
|
52
Simplex Trading
Chicago,
Illinois
| – | -$16K | -6,688 | Closed |
|
|
BFC
53
Bedel Financial Consulting
Indianapolis,
Indiana
| – | +$24 | +10 | New |
|
54
Bank of America
Charlotte,
North Carolina
| – | +$79 | +33 | New |
|
CTIC Hedge Fund Activity: Q2 2021 in Review
50 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2021, worth a combined $133M — up 5.6% from $126M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CTIC and 5 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 18 added.
The largest buyer was Stonepine Capital Management, adding an estimated $10.4M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $7.31M sold.
- 50 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2021, down from 55 in Q1 2021.
- Funds reported $133M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2021, up 5.6% quarter-over-quarter.
- 5 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2021 and 10 closed out, a net change of -5 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2021 was Stonepine Capital Management, an estimated $10.4M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2021 was Consonance Capital Management, an estimated $7.31M sold.
Based on aggregated 13F filings for Q2 2021.